Syngene International Ltd Share Price Today - Syngene International Ltd Stock Price Live NSE/BSE

Syngene International Ltd

NSE: SYNGENE BSE: 539268

₹478

(2.19)%

Tue, 03 Feb 2026, 00:25 pm

MTF 5xInvest in Syngene International Ltd with 5x Leverage Buy with MTF

Market Cap188.6B

PE Ratio54.55

Dividend0.27

Commercial Services

Miscellaneous Commercial Services

24.5K

1 Day

0 (0%)

No Result Found

Summary

Market Cap
18859.58
Net Profit
496.20
P/B
6.18
Sector P/E
55.05
P/E
58.89
EV/EBITDA
25.33
Debt/Equity (Industry)
0.40
Interest Cover (Industry)
5.30
ROCE (Industry)
11.32
RONW (Industry)
11.09
ROE
11.05
ROCE
13.37
Debt/Equity
0.13
EPS (TTM)
10.16
Dividend Yield
0.27
Book Value
117.51
Interest Cover
13.43

Analysis

all

Pros

Performance (ROE) is expected to be above the current IN Life Sciences industry average.
Syngene International's revenue growth is expected to exceed the India market average.
Syngene International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Syngene International is profitable, therefore cash runway is not a concern.
Syngene International is profitable, therefore cash runway is not a concern.

Cons

Unable to calculate sustainability of dividends as Syngene International has not reported any payouts.
Unable to evaluate Syngene International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Syngene International's dividend against the top 25% market benchmark as the company has not reported any payouts.
Syngene International's earnings are expected to grow by 1.5% yearly, however this is not considered high growth (20% yearly).
Syngene International's earnings growth is positive but not above the India market average.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	52.68	52.68	52.68	52.74	52.74
FII	14.96	16.31	16.50	19.47	20.64
DII	25.84	24.62	24.05	21.50	19.53
Public	6.52	6.38	6.77	6.29	7.09
Government	0	0	0	0	0

Technical Analysis

RSI

17.57

MACD

-46.95

50 DMA

615.74

200 DMA

642.04

Support and Resistance

Type	R1	R2	R3	PP	S1	S2	S3
Classic	962.53	751.28	612.37	540.03	401.12	328.78	117.53
Fibonacci	751.28	670.59	620.73	540.03	459.34	409.48	328.78
Camarilla	531.54	512.18	492.81	540.03	454.09	434.72	415.36

Pivots Level: Classic

+422.50

962.53

+211.25

751.28

+72.33

612.37

540.03

Pivot Point

LTP: 478

-138.92

401.12

-211.25

328.78

-422.50

117.53

Moving Average

SMAEMA

Period

Value

10-EMA
506.01
20-EMA
547.40
30-EMA
571.15
50-EMA
595.87
100-EMA
621.37
200-EMA
650.82

Announcement Date	Purpose	Action	Ex Date
22 Jan 2026	board-meetings	Quarterly Results
05 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
23 Apr 2025	dividend	₹1.25 Dividend /Share	27 Jun 2025
23 Apr 2025	agm
24 Apr 2024	agm
24 Apr 2024	dividend	₹1.25 Dividend /Share	28 Jun 2024
26 Apr 2023	dividend	₹0.50 Dividend /Share	30 Jun 2023
26 Apr 2023	agm
27 Apr 2022	agm
27 Apr 2022	dividend	₹0.50 Dividend /Share	01 Jul 2022

Syngene International Ltd

Narayana Hrudayalaya Ltd

Max Healthcare Institute Ltd

Fortis Healthcare Ltd

Global Health Ltd

Apollo Hospitals Enterprise Ltd

About Syngene International Ltd

Syngene International is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Syngene’s services include integrated drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&D, cGMP manufacturing, formulation and analytical development along with Clinical development services.

Industry

Miscellaneous

Founded

1993

Headquarters

CEO

Kiran Mazumdar Shaw

Employees

Contact

Website

http://www.syngeneintl.com

investor@syngeneintl.com; Mayank.Verma@syngeneintl

Phone

91-80-68915000/67758781

Location

Biocon SEZ Biocon Park, Plot No 2 & 3 Bommasandra Inds, Bengaluru, Karnataka, 560099

Year	History
2020	Syngene ties up with HiMedia Laboratories to manufacture ELISA test kits for COVID-19. Syngene joins global industry consortium to accelerate collaborative research in COVID-19 testing. Syngene and PharmAust collaborate to manufacture GMP-grade Monepantel for Human Clinical Trials. Bioprocessing Excellence Award 2020.
2021	Syngene receives India Pharma Awards 2021. Syngene Ranked As One Of The Top 100 Indian Wealth Creators For 2021. Syngene International extends long term research collaboration with Bristol Myers Squibb until 2030. Syngene through Biocon Foundation partners with NIMHANS for BHUMI.
2022	Syngene International takes top honors at CMO Leadership Awards 2022 for contract manufacturing. Syngene signs 10-year biologics manufacturing agreement with leading animal health company. Syngene and the Research and Innovation Circle of Hyderabad (RICH) launch scholarship program for women studying STEM subjects.
2023	Winner of India's Best Managed Companies 2023 programme Supply Chain Champion Award, 2023 Best Overall Sustainable Performance (Pharmaceutical) 2023 Biopharma Excellence Award (India Edition) 2023 Panbela announces issuance of new patent in Australia.
2024	Syngene received Pharmaceutical Technology Excellence Awards 2024. Syngene received Asia Pacific Biologics CMO Excellence Awards 2024. Syngene awarded CDMO Leadership Awards 2024. Syngene secures silver rating in EcoVadis sustainability index, ranking in top 15% of assessed companies. Syngene launches platform for rapid, enhanced protein production. Syngene International named as one of India's Best Managed Companies by Deloitte India.

Client Name	Order Side	QTY	Avg Price	Date
No Result Found

syngene international limited News

Syngene Intl drops 10.64% amid market decline

Syngene International shares fell 10.64% to Rs 485.95, becoming one of the top losers on Nifty Midcap 150. The company reported revenue of Rs 3,642.40 crore in 2025, up from Rs 3,488.60 crore in 2024.

27 Jan 2026

co actions results

Syngene Revises FY26 Outlook to 2-3% Decline

Syngene International has revised its FY26 growth forecast, now expecting a 2-3% decline compared to its previous prediction of mid-single digit growth, marking a significant shift in the company's outlook.

23 Jan 2026

co actions results

Syngene Pays ₹20,000 Fine for Committee Non-Compliance

Syngene International paid ₹20,000 plus GST fine to stock exchanges for non-compliance with Nomination & Remuneration Committee composition requirements under SEBI regulations during Q2 FY26.

22 Jan 2026

stocks

Syngene Q3FY26 Results: Profit Drops 86.6% YoY

Syngene International reports Q3FY26 standalone profit of ₹165 million, down 86.6% YoY from ₹1,231 million. Revenue declined 4.9% to ₹8,344 million amid exceptional charges of ₹658 million.

22 Jan 2026

co actions results

Syngene extends Bristol Myers partnership till 2035

Syngene International announced extension of its strategic research collaboration with Bristol Myers Squibb until 2035, expanding the 25-year partnership to include integrated services across the entire drug development lifecycle.

19 Jan 2026

stocks

Showing 1–5 of 58

Rows per page:

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800